Furthermore, maraviroc, a CCR5 antagonist, restored antitumor immunity in orthotopically transplanted pancreatic tumors in mice, indicating that targeting the CCL5–CCR5 axis is a promising immunotherapy for PDAC. The gene discussed is CCL5; the disease is pancreatic neoplasm.